Adherence to interferon β-1a therapy using an electronic self-injector in multiple sclerosis: a multicentre, single-arm, observational, phase IV study
暂无分享,去创建一个
Anthony Feinstein | A. Feinstein | Virginia A. Devonshire | Patrick Moriarty | P. Moriarty | V. Devonshire
[1] W. L. Benedict,et al. Multiple Sclerosis , 2007, Journal - Michigan State Medical Society.
[2] C. Poser,et al. Diagnostic criteria for multiple sclerosis , 2001, Clinical Neurology and Neurosurgery.
[3] Hirofumi Ochi,et al. [Cognitive impairment in multiple sclerosis]. , 2014, Brain and nerve = Shinkei kenkyu no shinpo.
[4] D. Centonze,et al. Patient adherence to and tolerability of self-administered interferon β-1a using an electronic autoinjection device: a multicentre, open-label, phase IV study , 2012, BMC Neurology.
[5] S. Sorbi,et al. A short version of Rao's Brief Repeatable Battery as a screening tool for cognitive impairment in multiple sclerosis , 2009, The Clinical neuropsychologist.
[6] Arthur L. Allen,et al. Factors that influence adherence with disease-modifying therapy in MS , 2009, Journal of Neurology.
[7] A. Lugaresi. Addressing the need for increased adherence to multiple sclerosis therapy: can delivery technology enhance patient motivation? , 2009, Expert opinion on drug delivery.
[8] P. Fontoura,et al. The Global Adherence Project (GAP): a multicenter observational study on adherence to disease‐modifying therapies in patients with relapsing‐remitting multiple sclerosis , 2011, European journal of neurology.
[9] A. Lugaresi,et al. Patient-rated suitability of a novel electronic device for self-injection of subcutaneous interferon beta-1a in relapsing multiple sclerosis: an international, single-arm, multicentre, Phase IIIb study , 2010, BMC neurology.
[10] E. Verdun,et al. The MS Choices Survey: findings of a study assessing physician and patient perspectives on living with and managing multiple sclerosis , 2011, Patient preference and adherence.
[11] M. Reynolds,et al. Persistence and adherence to disease modifying drugs among patients with multiple sclerosis , 2010, Current medical research and opinion.
[12] David H. Miller,et al. Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial , 2009, The Lancet Neurology.
[13] D. Goodkin,et al. Injectable medication for the treatment of multiple sclerosis: The influence of self-efficacy expectations and infection anxiety on adherence and ability to self-inject , 2001, Annals of behavioral medicine : a publication of the Society of Behavioral Medicine.
[14] Cyril F. Chang,et al. Impact of Adherence to Interferons in the Treatment of Multiple Sclerosis , 2010, Clinical drug investigation.
[15] S. De Geest,et al. Adherence to Long-Term Therapies: Evidence for Action , 2003, European journal of cardiovascular nursing : journal of the Working Group on Cardiovascular Nursing of the European Society of Cardiology.
[16] C. D’Arcy,et al. Patient assessment of an electronic device for subcutaneous self-injection of interferon β-1a for multiple sclerosis: an observational study in the UK and Ireland , 2012, Patient preference and adherence.
[17] Jeffrey A. Cohen,et al. Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria , 2011, Annals of neurology.
[18] J. DeLuca,et al. Cognitive impairment in multiple sclerosis , 2008, The Lancet Neurology.
[19] A. Lugaresi. RebiSmart™ (version 1.5) device for multiple sclerosis treatment delivery and adherence , 2013, Expert opinion on drug delivery.
[20] A. Lippman. Adherence to medication. , 2005, The New England journal of medicine.
[21] S. Reingold,et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria” , 2005, Annals of neurology.
[22] Scott B Patten,et al. Regional variation of multiple sclerosis prevalence in Canada , 2005, Multiple sclerosis.
[23] Emilio Portaccio,et al. Multiple sclerosis-related cognitive changes: A review of cross-sectional and longitudinal studies , 2006, Journal of the Neurological Sciences.
[24] H. Tremlett,et al. Interrupted therapy , 2003, Neurology.
[25] P. Panegyres,et al. Cognitive impairment in multiple sclerosis: Evidence-based analysis and recommendations , 2007, Journal of Clinical Neuroscience.
[26] P. Sørensen,et al. The changing demographic pattern of multiple sclerosis epidemiology , 2010, The Lancet Neurology.
[27] J. Haselkorn,et al. Injection anxiety remains a long-term barrier to medication adherence in multiple sclerosis. , 2009, Rehabilitation psychology.
[28] Jared M. Bruce,et al. Objective adherence monitoring in multiple sclerosis: initial validation and association with self-report , 2010, Multiple sclerosis.
[29] J. Stephenson,et al. Impact of adherence to disease-modifying therapies on clinical and economic outcomes among patients with multiple sclerosis , 2011, Advances in therapy.
[30] C. Spielberger,et al. Manual for the State-Trait Anxiety Inventory , 1970 .
[31] D. Sobieraj,et al. Dosing frequency and medication adherence in chronic disease. , 2012, Journal of managed care pharmacy : JMCP.
[32] S. Agarwal,et al. Comparison of adherence and persistence among multiple sclerosis patients treated with disease-modifying therapies: a retrospective administrative claims analysis , 2011, Patient preference and adherence.
[33] T. Gomes,et al. Adherence to Multiple Sclerosis Disease-Modifying Therapies in Ontario is Low , 2011, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.